Almonty Closes $700M Convertible Note Offering, Boosts Liquidity Ahead of Sangdong Ramp

What happened

Almonty Industries closed a significantly oversubscribed $700 million convertible senior notes offering (2.25% due 2031), including full exercise of the over-allotment option, netting substantial cash proceeds with a low coupon. The proceeds provide ample liquidity to fund Sangdong's commissioning, Phase II expansion, and the Gentung Browns Lake project, reducing the near-term risk of equity dilution at depressed prices. However, this debt adds $700 million in principal obligations to a balance sheet already carrying negative interest coverage (-4.84x) and negative free cash flow (-$24.8M as of Sep 2025). While the offering underscores strong institutional demand for Almonty's non-China tungsten narrative, it does not resolve the critical missing proof point: repeatable saleable concentrate shipments with disclosed grade and payables. Until Sangdong demonstrates stable commercial output, the stock's $14.16 price still prices success rather than reality, and the note's conversion feature creates potential overhang if shares trade near the conversion price.

Implication

The $700M convertible note significantly de-risks Almonty's funding for the next 12-18 months, allowing it to complete plant commissioning and potentially accelerate Phase II without dilutive equity. The 2.25% coupon is attractive and suggests strong institutional confidence in the tungsten thesis. However, the conversion feature (likely at a premium to current price) will cap upside if shares underperform, and the debt burden increases financial risk if commissioning extends into 2027. Investors should monitor Sangdong's first saleable shipments and any disclosure of oxide conversion facility timing. Without operational data, the stock remains speculative; the attractive entry point is $11, and the stock should be trimmed above $18 until execution is proven.

Thesis delta

The convertible note offering shifts Almonty's capital structure from an equity-heavy build story to a debt-financed execution story, reducing immediate dilution risk but adding fixed obligations. This does not change the WAIT rating because the core thesis still hinges on Sangdong achieving stable commercial output—a proof point that remains undisclosed. The improved liquidity buys time, but the stock's elevated valuation (P/B >24x) still prices a successful ramp that has not materialized.